Javier Cortés, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, talks on potential new drugs for the treatment of metastatic triple-negative breast cancer (TNBC) which may have a future role in the treatment of early TNBC. In particular, Dr Cortés discusses the role of antibody-drug conjugates (ADCs) including sacituzumab govitecan, which targets Trop-2, trastuzumab deruxtecan in HER2-low breast cancer, and ladiratuzumab, which targets LIV-1. Dr Cortés also comments on the benefits observed with olaparib therapy in patients with breast cancer. This interview took place at the virtual European Society for Medical Oncology (ESMO) Breast Cancer Congress 2021
Transcript (edited for clarity)
This talk belongs to the early breast cancer, triple-negative breast cancer symposium. So, why do I speak about potential new drugs with activity in metastatic breast cancer? Because I think that these potential new drugs will become the future good options for early triple-negative breast cancer. So, I think, or this is why I think this talk is important for a meeting in the early breast cancer setting...
This talk belongs to the early breast cancer, triple-negative breast cancer symposium. So, why do I speak about potential new drugs with activity in metastatic breast cancer? Because I think that these potential new drugs will become the future good options for early triple-negative breast cancer. So, I think, or this is why I think this talk is important for a meeting in the early breast cancer setting.
So, which are the potential new drugs that have been discussed, and I would like to highlight? Maybe the most important ones, the most exciting ones are the antibody-drug conjugates. And with the data we have today, and also, we have to remember another antibody-drug conjugate that was presented at ESMO Breast this year. But I would like to start with sacituzumab govitecan. Basically, or in brief, this is an antibody-drug conjugate against Trop-2, with beautiful data in a randomized Phase III study in the third line or beyond triple-negative breast cancer, showing an impressive improvement in not only progression-free survival, but also overall survival, and overall response rate. Another anti Trop-2 was presented at ESMO Breast, as I said before, with very, very preliminary interesting data in TNBC.
So, I think that these drugs will move earlier on time in the, in the, in the early triple-negative breast cancer setting. Of course, we also discussed, what I think is something of interest, another antibody-drug conjugate, such as trastuzumab deruxtecan against low HER2, or ladiratuzumab against LIV-1. So, different antibody-drug conjugates with great activity.
Of course, we discussed also the role of immunotherapy, which also moved into the early breast cancer setting. And finally, some comments about the PARP inhibitors and the AKT inhibitors, interesting drugs that also will move into the early breast cancer setting. We should not forget, and I finish with that, that olaparib has shown promising data in the adjuvant setting for patients with germline BRCA mutations.
So, many good drugs which are upcoming, which are being tested in the metastatic setting, that hopefully in the very near future, also, we’ll see some interesting data in the early breast cancer disease. And this is important because this is the objective to cure more and more patients in the future.
Javier Cortés, MD, PhD, has participated in a consulting/advisory role for Roche, Celgene, Cellestia, AstraZeneca, Biothera Pharmaceutical, Merus, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Servier, Merck Sharp&Dohme, GSK, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim and Kyowa Kirin; has received honoraria from Roche, Novartis, Celgene, Eisai, Pfizer, Samsung Bioepis, Lilly, Merck Sharp&Dohme and Daiichi Sankyo; has received institutional research funding from Roche, Ariad pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer healthcare, Eisai, F.Hoffman-La Roche, Guardanth health, Merck Sharp&Dohme, Pfizer, Piqur Therapeutics, Puma C and Queen Mary University of London; holds stock, patents and intellectual property in MedSIR; and has received travel, accommodation and expenses from Roche, Novartis, Eisai, Pfizer, Daiichi Sankyo.